The prognosis of lung cancer patients with high expression of STEAP2 was significantly better than that of lung cancer patients with a low expression of STEAP2 (HR 0.8 [95% confidence interval 0.68–0.94]; log-rank P = 0.0074) and STEAP2, suggesting poor patient prognosis. Here, STEAP2 is linked to lung carcinoma.